Afaxys

Afaxys

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

Afaxys is a specialized generic drug company with a clear social mission to improve access to affordable reproductive healthcare. It operates as a commercial-stage enterprise, marketing a portfolio of AB-rated generic oral contraceptives, the over-the-counter emergency contraceptive EContra One-Step, and the contraceptive patch Twirla (as a promotional partner). The company's core strategy involves partnering with federally qualified health centers, clinics, and public health providers to ensure a stable supply of essential medications for underserved populations, positioning itself as a key supplier in this niche segment of the generic drug market.

Reproductive HealthWomen's Health

Technology Platform

Specialized commercial and distribution model for generic pharmaceuticals focused on public health clinics and safety-net providers, ensuring reliable supply and stable pricing.

Funding History

2
Total raised:$75M
Debt$50M
Series A$25M

Opportunities

The company is positioned to benefit from stable or growing public funding for reproductive health services and the expanded OTC market for emergency contraception.
Its deep relationships with safety-net clinics provide a defensible niche against larger generic competitors.

Risk Factors

High dependence on public health funding policies and a single customer channel (clinics) creates vulnerability to political and budgetary shifts.
Intense competition from large generic drug makers and potential supply chain disruptions for its sourced products are significant threats.

Competitive Landscape

Afaxys competes with large generic pharmaceutical companies (e.g., Teva, Viatris) that market similar contraceptive products broadly, but it differentiates through its focused mission, clinic-centric service model, and commitment to stable pricing. Its primary competition for clinic contracts likely comes from other specialty distributors and the generic arms of larger drug companies.